ADVERTISEMENT
LIVE DESK·Global markets desk·Last updated 14s ago
ADVERTISEMENT
Markets/EquitiesArticle

Tel Aviv stocks rise 0.35% as insurance, biotech shares gain

The TA 35 index advanced 0.35% Tuesday, led by gains in insurance and biomedical stocks, while ICL Israel Chemicals and NICE led decliners. Crude oil futures fell over 3%.

PA
Priya Anand · Equities & Earnings Desk · 29 Aug 2026 · 20:57 · 1 min read
Share
Tel Aviv stocks rise 0.35% as insurance, biotech shares gain

The Tel Aviv Stock Exchange’s benchmark TA 35 index rose 0.35% on Tuesday, August 25, 2026, as gains in the insurance and biomedical sectors offset broader weakness.

Advancing issues narrowly trailed decliners by 235 to 236, with 88 stocks unchanged. The index’s modest gain followed a session in which insurance shares such as Migdal Insurance and Clal Insurance Enterprises Holdings led advancers, while industrial and technology names weighed on the broader market.

Among the top performers, Camtek Ltd led with a 3.39% rise to 43,250 points, adding 1,420 points. Migdal Insurance climbed 3.14% to 1,905 points, and Clal Insurance Enterprises Holdings gained 3.14% to 25,320 points. The largest decliners included ICL Israel Chemicals, which fell 4.43% to 1,660 points, Next Vision Stabilized Systems down 4.05% to 20,380 points, and NICE Ltd, which dropped 2.79% to 29,600 points.

Commodities futures declined as crude oil prices extended losses. October-delivery U.S. crude oil futures fell 3.06% to $82.41 per barrel, while November Brent crude dropped 2.96% to $87.86 per barrel. December gold futures slipped 0.13% to $4,691.91 per troy ounce.

The Israeli shekel firmed against major currencies, with the USD/ILS pair declining 0.78% to 2.98 and the EUR/ILS pair receding 0.75% to 3.48. The U.S. Dollar Index futures rose 0.03% to 98.90.

This article was produced with AI assistance and edited by a Finance Review Daily journalist.
ADVERTISEMENT
Share this story
PA
Written by
Priya Anand
Equities & Earnings Desk

Priya covers listed equities and corporate earnings, reading quarterly results and guidance for what they signal about sector health and forward valuations.

More from Priya Anand →
ADVERTISEMENT
ADVERTISEMENT